Abivax Reports Positive Phase 3 UC Data, Secures €637.5M Financing, Extends Cash Runway

summarizeSummary

Abivax reported positive Phase 3 data for its lead UC drug candidate, obefazimod, and successfully raised €637.5 million in a July 2025 offering, extending its cash runway into Q4 2027, significantly de-risking its development path.

check_boxKey Events

• Positive Phase 3 UC Induction Data

  In July 2025, Abivax announced positive top-line data from its two pivotal Phase 3 ABTECT induction trials for obefazimod in moderately to severely active ulcerative colitis (UC), demonstrating significant clinical remission rates compared to placebo.

• Substantial Capital Raise

  The company completed a public offering in July 2025, raising approximately €637.5 million in gross proceeds by issuing 11,679,400 ADSs at $64.00 per ADS, significantly bolstering its financial position.

• Extended Cash Runway

  The successful financing is expected to fund operations into the fourth quarter of 2027, providing a 12-month cash runway following the planned New Drug Application (NDA) submission for obefazimod in UC.

• Debt Conversions and Prepayments

  During July-December 2025, Heights convertible notes and Kreos/Claret OCABSA/BSA were converted into ordinary shares, and Tranches B and C of the Kreos/Claret bond loans were fully prepaid, streamlining the company's debt structure.

auto_awesomeAnalysis

Abivax S.A. filed its annual 20-F report for the fiscal year ended December 31, 2025, highlighting significant progress in its lead drug candidate, obefazimod, and a substantial capital raise. The company announced positive top-line data from its two Phase 3 induction trials for obefazimod in ulcerative colitis (UC) in July 2025, a critical de-risking event for its lead asset. This clinical success was followed by a major public offering in July 2025, raising approximately €637.5 million in gross proceeds, which significantly extended the company's cash runway into the fourth quarter of 2027. Additionally, Abivax converted convertible notes and warrants into ordinary shares and prepaid other debt, simplifying its capital structure. While the company reported increased net losses for 2025 and acknowledged ongoing material weaknesses in internal controls, these are common for clinical-stage biotechs and are being addressed. The positive clinical data and robust financing are strong indicators of progress towards commercialization and financial stability, despite potential future challenges from new EU pharmaceutical legislation and US healthcare reforms.